Sana Q1 net loss $47.2M, cash $101.1M; Mayo $25M equity; SC451/SG293 trials on track for 2026

Sana Biotechnology, Inc.

2026-Q1 EPS reported -$0.17

Net loss of $47.2M ($0.17/sh); R&D expenses $28.7M (down from $37.2M YoY).
Cash & securities $101.1M; pro forma $128.9M including Mayo $25M equity and ATM activity.
Mayo collaboration to accelerate SC451; Mayo made $25M equity investment with option for another $25M.
SC451 Phase 1 IND filing expected later this year; SG293 clinical data presented May 12 at ASGCT.
SG227 (BCMA CAR) expected to begin clinical testing as early as mid-2027, contingent on SG293 data.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sana Biotechnology, Inc. reported financial results for first quarter 2026.

Period: first quarter 2026
Result: reported results

Exact text from the filing

On May 11, 2026, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Sana Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-216758

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.